A gonadotropin-releasing hormone analogue impairs glucose tolerance in a diabetic patient.
Changes in serum glucose levels were examined in a female with insulin-independent diabetes who received a gonadotropin-releasing hormone (GnRH) analog treatment for pelvic endometriosis. The mean blood glucose levels were higher on busereline therapy, and higher levels of hemoglobin A1c were noted on busereline therapy (range 6.9-12.5%) versus pre- and post-treatment (range 5.1-5.9%). Hormonal alteration induced by GnRH analog treatment may impair glucose tolerance.
Imai
A
A
Department of Obstetrics and Gynecology, Gifu University School of Medicine, Japan.
Takagi
A
A
Horibe
S
S
Fuseya
T
T
Takagi
H
H
Tamaya
T
T
D000328:Adult; D001786:Blood Glucose / Q000378:metabolism*; D002064:Buserelin / Q000009:adverse effects* / Q000627:therapeutic use; D003613:Danazol / Q000627:therapeutic use; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000150:complications*; D004715:Endometriosis / Q000150:complications / Q000188:drug therapy*; D004965:Estrogen Antagonists / Q000627:therapeutic use; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans
D001786:Blood Glucose; D002064:Buserelin; D003613:Danazol; D004965:Estrogen Antagonists; D006442:Glycated Hemoglobin